Product Description
VIR-1111 is being developed by Vir Biotechnology for the treatment of patients with HIV I Infection. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04725877?term=VIR-1111&draw=2&rank=1)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vir Biotechnology
Company Location: SAN FRANCISCO CA 94158
Company CEO: George Scangos
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Acquired Immunodeficiency Syndrome|HIV Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VIR-1111 | P1 |
Completed |
HIV Infections|Acquired Immunodeficiency Syndrome |
2022-12-05 |
70% |